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Extracellular vesicles are membrane- enclosed nano-
scale particles released from essentially all prokary-
otic and eukaryotic cells that carry proteins, lipids, RNA 
and DNA. They can deliver information between cells 
through the extracellular space, with strong evidence 
for functional activity provided by their phenotypic 
effects on recipient cells. Cargo RNAs of extracellular 
vesicles include various biotypes that represent a selected 
portion of the RNA content of the source cell, with a 
strong bias towards small non- coding RNAs, although 
fragmented and intact mRNA, ribosomal RNA (rRNA) 
and long non- coding RNA (lncRNA) molecules can be 
found. Ample evidence supports the ability of RNAs 
enclosed in extracellular vesicles to impact the func-
tional properties of cells that take them up (Table 1). For 
example, extracellular vesicles in plasma promote repair 
of cardiac cells1, vesicles released by astrocytes contribute 
to neurodegeneration2 and tumour- derived vesicles cre-
ate a favourable microenvironment for cancer progres-
sion3 and metastases4. However, given that the functions 
of many non- coding RNAs (ncRNAs) are incompletely 
understood and that delivery of any given extracellu-
lar vesicle- associated RNA is accompanied by delivery 
of multiple other biomolecules, the complex language of 
extracellular vesicle- mediated communication remains 
to be deciphered. Moreover, the cellular mechanisms 
involved in the trafficking and fate of extracellular RNAs 
(exRNAs), including the possibility of packaging differ-
ent RNA sequences into different types of extracellular 
vesicles, differential uptake into specific recipient cell 
types and fate on uptake are still being elucidated (Fig. 1).
The RNA contained in extracellular vesicles reflects 
the type and the physiological/pathological state of the 
source cells, but differs substantially from the cellular 
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RNA content, in terms of both the types of RNA and 
the relative concentrations of specific RNA sequences. The 
extracellular vesicle populations carried in bio fluids, tis-
sues and conditioned medium from cultured cells are 
heterogeneous with respect to size, morphology and 
composition. Four major subclasses of extracellular ves-
icles appear to arise from distinct biogenesis pathways 
and can be distinguished roughly in the basis of size: 
exosomes (50–150 nm), microvesicles (100–1,000 nm), 
large oncosomes (1,000–10,000 nm) and apoptotic bodies 
(100–5,000 nm), but are difficult to distinguish from 
high- density and low- density lipoproteins, chylomi-
crons, protein aggregates and cell debris5. Guidelines for 
standardization of terminology, methods and reporting 
are being developed to improve experimental repro-
ducibility across studies6,7. The size of most extracellular 
vesicles (which also limits the number of cargo mol-
ecules/vesicles) places them below the resolution and 
sensitivity thresholds of standard light micros copy 
and fluorescence- activated sorting techniques. Overlap 
in the sizes and other biophysical properties among 
different extracellular vesicle subclasses and lack of 
known unique markers for each subclass8,9 have made 
it difficult to define the cargo (including RNAs) of dif-
ferent subclasses with confidence5. Technical factors, 
including the use of different methods for isolation of 
extracellular vesicles and their RNA, can strongly influ-
ence RNA profiling results (see, for example, reFs10–16). 
Separation of RNA in vesicles from RNAs associated 
with other exRNA carriers, including lipoproteins17 and 
ribonucleoproteins18, is also challenging (see reFs5,6,10,17,18 
and the exRNA Atlas11). A variety of approaches have 
been used to address these concerns, including culture 
of cells in serum- free medium (to avoid contamination 
with serum- derived extra cellular vesicles) and separa-
tion of extracellular vesicle subclasses and other exRNA 
Table 1 | Functional delivery of mirNas by extracellular vesicles
Source cell rNa Target cell effect refs
Rhabdomyosarcoma miR-486-5p Mouse embryonic 
fibroblasts, C2C12 
immortalized mouse 
myoblast cell line, 
immortalized myoblasts
Cell migration, invasion, colony 
formation (in vitro)
258
Glioblastoma miR-9 miR-21 Brain endothelial cells Angiogenesis (in vitro) 3,259
Microglia Immunosuppression (in vivo)
Breast cancer cells Various Epithelial cells Promote tumorigenesis, invasion, 
cell proliferation (in vitro)
260
Endothelial cells Promote angiogenesis (in vitro)
Breast cancer cells Increase drug resistance (in vitro)
miR-9, miR-195, 
miR-203
Cancer stem cells Increase expression of stemness 
genes (in vitro and in vivo)
261
Cardiac progenitor 
cells
miR-210, miR-132, 
miR-21, miR-451, 
miR-146a
Various Inhibit apoptosis, promote 
angiogenesis, improve cardiac 
function, inhibit myocardial 
fibrosis (in vitro and in vivo)
Reviewed 
in262
Cardiomyocytes miR-320 Various cell types Inhibit angiogenesis (in vivo) Reviewed 
in263
miR-30a Regulate autophagy (in vitro)
miR-29b, miR-455 Inhibit fibrosis (in vivo)
miR-27a, 
miR-28-3p, 
miR-34a
Contribute to oxidative stress 
(in vitro)
miR-208a Promote fibrosis (in vivo)
Neuroprecursor cells miR-21a Neural progenitor cells Promote neurogenesis (in vitro) 264
Adipose macrophage miR-155 Bone marrow 
mesenchymal stem cells
Increase insulin resistance (in vitro 
and in vivo)
265
Adipose 
mesenchymal stem 
cells
miR-375 Bone marrow 
mesenchymal stem cells
Osteogenic differentiation, 
enhance bone regeneration 
(in vitro and in vivo)
266
Adipocytes (from 
brown adipose tissue)
miR-99b Liver Increase Fgf21 expression, 
increase glucose tolerance (in vivo)
267
miRNA , microRNA.
Large oncosomes
extracellular vesicles between 
1,000 nm and 10,000 nm in 
diameter derived from tumour 
cells that contain abnormal 
and transforming 
macromolecules, in addition  
to other cargo.
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carriers by high-resolution density gradient centrifugation10, 
size-exclusion chroma tography19, asymmetric field- flow 
fractionation20,21 and immunoaffinity purification9.
In addition to serving as a novel mode of communi-
cation among cells, RNAs in extracellular vesicles can 
also serve as biomarkers and therapeutics for a variety 
of diseases. Since extracellular vesicles have been found 
in all tested biofluids, many of which can be collected 
non- invasively, the RNAs within them can be interro-
gated in real time to evaluate the functional state of a 
range of cell and tissue types22. The potential of extra-
cellular vesicles to protect nucleic acids and other 
biological macromolecules from degradation in vivo, 
and to deliver them to recipient cells in a targeted man-
ner without immune activation, makes them an excit-
ing new modality for delivery of RNA therapeutics, 
including small interfering RNAs (siRNAs), microRNAs 
(miRNAs), antisense oligonucleotides, mRNAs, guide rNas 
and self- amplifying rNas.
In this Review, we discuss the biogenesis, biological 
functions and emerging clinical applications of extra-
cellular vesicle RNAs in mammalian cells. Throughout, 
we highlight the key open questions and technical chal-
lenges that currently limit the broader translational 
use of extracellular vesicles. We are optimistic that 
these hurdles will be overcome soon, allowing better 
understanding and control of extracellular vesicle- 
mediated delivery of RNAs to specific cellular targets 
and opening up new opportunities for the detection and 
treatment of various diseases, including cardiovas-
cular, neurodegenerative and metabolic diseases and 
cancers.
Extracellular vesicles as RNA carriers
Extracellular vesicles carry within them a wide vari-
ety of RNA sequences representing many biotypes of 
RNA. This diversity of RNAs, as well as the small size 
and heterogeneity of extracellular vesicles and the over-
all low concentration of RNA in extracellular vesicles, 
has complicated characterization of the RNA cargo of 
extracellular vesicle subclasses (box 1; Table 2).
Extracellular vesicle RNA content. To understand inter-
cellular communication mediated by extracellular ves-
icle RNAs, it is important to develop a comprehensive 
catalogue of the types of RNAs and sequences within 
them. Initial studies reported that extracellular vesicles 
contained mRNAs and mature miRNA sequences, as 
well as ncRNAs, with a peak size of 200 nucleotides, 
but extending out to 5 kb or more23–25. Since then, more 
comprehensive studies have found the majority of 
known ncRNA biotypes, including small nuclear rNas, 
small nucleolar rNas (snoRNAs), rRNAs, lncRNAs, 
PiWi- interacting rNas (piRNAs), transfer RNAs (tRNAs), 
mito chondrial RNAs, Y rNas and vault rNas (vtRNAs)26–28. 
miRNA precursors (pre- miRNAs) have also been 
reported in tumour microvesicles, along with the RNA 
interference processing machinery components Dicer 
and argonaute29–31. However, the methods used in these 
studies did not separate extracellular vesicles from free 
ribonucleoproteins16 or lipoproteins32. Moreover, among 
the many studies using proteomic methods to analyse the 
composition of extracellular vesicles, only one has 
reported the presence of Argonaute 2 (AGO2)33, and 
none has detected Dicer. One study that used density 
Lipoproteins
Macromolecular aggregates of 
proteins (apoproteins) and 
different classes of hydrophobic 
and amphipathic biomolecules 
that range in size from 10 nm 
to 1 μm. These aggregates  
have the function of collecting 
and transporting lipids, 
triglycerides, free cholesterol 
(unesterified cholesterol) and 
esterified cholesterol in blood 
plasma.
Ribonucleoproteins
Proteins structurally associated 
with nucleic acids, the 
prosthetic group (nucleic acid) 
of which contains ribose.
High- resolution density 
gradient centrifugation
a method in which extracellular 
vesicles and particles are 
centrifuged in a gradient 
medium (for example, iodixanol) 
and separated primarily on the 
basis of their density.
Size- exclusion 
chromatography
a technique in which a porous 
stationary phase is used to sort 
extracellular vesicles from 
proteins on the basis of the 
larger size of the former.
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Fig. 1 | Principles of functional cell communication by extracellular vesicle rNa. Extracellular vesicles are generated 
as highly heterogeneous populations with different types of RNA cargo within them and in different amounts and 
proportions. Functionally , these RNAs can be divided into those with known functions, for example some mRNA , 
microRNA (miRNA) and small interfering RNA (green zone), those with predicted functions, for example, some transfer 
RNA , small nucleolar RNA , small nuclear RNA , Y RNA and vault RNA (blue zone) and those with unknown functions, for 
example, fragmented and degraded (methylated and uridylidated) RNA species (orange zone). This heterogeneity is 
further enhanced by the fact that extracellular vesicle cargo content strongly depends on the context (for example, cell 
type, stimuli and treatments). The effect that different kinds of RNA in vesicles can have on recipient cells is dictated in 
part by the nature of these cells, which will show differential capability for recognizing specific vesicles, their uptake and 
ultimately their functional effect.
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gradient ultracentrifugation to isolate extracellular ves-
icles from cell culture supernatant of cancer cells did 
convincingly demonstrate that overexpression of the 
KRAS oncogene promotes sorting of AGO2- associated 
miRNAs into extracellular vesicles34. Thus, whether 
pre- miRNAs and their processing machinery are trans-
ferred via extracellular vesicles in normal cells remains 
to be established. Finally, extracellular vesicle- associated 
circular rNas have also been detected by use of specific 
data analysis pipelines that can identify back- spliced 
transcripts35–40.
In general, RNA in extracellular vesicles can be 
categorized into three types: RNAs that have been 
established to be functional when carried by extracel-
lular vesicles between cells, such as intact mRNAs and 
miRNAs; intact RNAs that are predicted to be functional 
but have not been definitively demonstrated to medi-
ate intercellular communication (for example, piRNAs 
and vtRNAs); and fragments of RNAs (for example, 
trNa fragments and fragments of mRNAs and rRNAs), 
some of which may be functional but others may be 
non- functional degradation products (Fig. 1).
Specific enrichment of RNAs in extracellular vesicles. 
The transcriptomes of different cell types are partially 
reflected in their extracellular vesicle RNA cargo14,41, but 
the RNA profiles of extracellular vesicles differ substan-
tially from those of their cells of origin24,42–44, suggesting 
that some RNA species are selectively incorporated into 
extracellular vesicles. A recent small RNA- sequencing 
study focusing on 17–35 nucleotide sequences from 
extracellular vesicles across five cell lines found that 
rRNA fragments accounted for 30–94% of the reads 
and ‘small RNAs’ accounted for 2–40% of the reads, 
depending on the cell type41. In the ‘small RNA’ cate-
gory, approximately 15% in some lines and nearly 80% 
in others mapped to miRNAs, which inversely correlated 
with the abundance of piRNAs (ranging from 80% to 
20%). Notably all of the cell lines included in that study 
were highly aneuploid, and therefore the results might 
not reflect the RNA composition of extracellular vesicles 
in cells with normal genomic composition.
In addition to these differences in RNA biotypes, 
specific RNA sequences are packaged into extra cellular 
vesicles with different efficiencies. Early studies focused 
on preferential loading of specific miRNAs into extra-
cellular vesicles45,46, and a recent study found that 
during T cell activation, tRNA fragments are preferen-
tially enriched in extracellular vesicles compared with 
miRNAs47. The physiological states of cells can also 
impact exRNA profiles, including oxidative stress48, 
pain49 and exercise50–52, all of which alter levels of spe-
cific extracellular miRNAs in conditioned medium from 
cultured cells, as well as in patient serum/plasma.
Packaging of extracellular vesicle RNA
Biogenesis of extracellular vesicles is relatively well 
studied, and several modes and molecular components 
that drive the process have been established5,53 (Fig. 2). 
Exosomes are generated by invagination of the endo-
somal membrane forming intraluminal vesicles within 
multivesicular bodies (MVBs). This process involves 
participation of the endosomal sorting complex requi-
red for transport, as well as RAB27A/RAB27B, tumour 
susceptibility gene 101 protein (TSG101), ALIX, vacu-
olar protein sorting- associated protein 4 (VPS4)5 and 
Box 1 | Technical considerations in characterization of extracellular vesicle rNa cargo
Different rNa isolation and measurement methods will produce different extracellular rNa (exrNa) profiles from the 
same biofluid or rNa sample9,11,16,24,112,285–291 owing to:
•	unique properties of each exrNa carrier type, such as susceptibility to different chemical disruption methods
•	biases of each rNa isolation and profiling method
Quantification of the stoichiometry of extracellular vesicle cargo is difficult because:
•	there are low numbers of cargo molecules per vesicle. On average, only one microrNa per extracellular vesicle35 to one 
microrNa per 100 extracellular vesicles292 and one intact long rNa molecule (for example, a full- length mrNa) per 
1,000 extracellular vesicles112
•	most sensitive methods (quantitative reverse transcription–PCr and Droplet Digital PCr) are tailored to specific rNa 
species. However, different rNa sequences can differ greatly in abundance, so it is difficult to accurately extrapolate 
measurements obtained for one specific rNa to other rNas
•	rNa biotypes are not evenly distributed among the different extracellular vesicle subtypes112,135
•	concordance among existing methods for quantification of extracellular vesicles is poor293–295
•	single- vesicle characterization methods (for example, through simultaneous visualization of extracellular vesicle 
protein markers and rNa cargo by super- resolution microscopy296) are needed. Current methods are targeted and of 
low throughput
Different strategies can be applied to allow profiles from different biological groups (for example, cases and controls for a 
given disease) to be reliably compared:
•	use the same method throughout a study. intramethod reproducibility of many exrNa isolation and analysis methods is 
quite high, so consistent use of the same method allows differential expression studies to be performed
•	use computational approaches to separate (or deconvolute) the data from a mixed population of exrNa carriers into 
profiles of the component carrier subclasses11
Candidate biomarkers and signalling rNas identified by comprehensive exrNa profiling methods should be validated:
•	biomarkers should be validated in multiple independent study populations
•	candidate signalling rNas should be functionally validated by multiple approaches
Asymmetric field- flow 
fractionation
a technique that separates 
differentially sized particles 
ranging from 1 nm to 100 μm  
in a fluid suspension where  
the rate of laminar flow is not 
uniform. a force is applied in  
a perpendicular direction, 
facilitating the separation of 
particles on the basis of size.
Immunoaffinity purification
a method of isolation of 
extracellular vesicles using 
antibodies, typically 
conjugated to magnetic beads, 
that recognize proteins 
exposed on the surface of 
extracellular vesicles.
Antisense oligonucleotides
sequences of DNa or rNa 
roughly 15–25 nucleotides in 
length that hybridize to 
complementary rNa targets, 
resulting in altered splicing or 
degradation of the targeted 
rNa.
Guide RNAs
rNas with a specific sequence 
that recognize and aid 
nucleases, such as Cas9, in 
cutting the genomic DNa 
region of interest for targeted 
genome engineering.
Self- amplifying RNAs
engineered viral genomes 
encoding proteins involved in 
the replication mechanism and 
therefore capable of directing 
their own replication.
Small nuclear RNAs
short sequences (about 150 
nucleotides) of ribonucleic 
acid, usually very rich in uracil, 
involved in the maturation of 
mrNa in the cell nucleus.
Small nucleolar RNAs
(snorNas). rNa species 
consisting of 60–300 
nucleotides capable of 
promoting certain chemical 
modifications and maturation 
of many cellular rNas.
PIWI- interacting RNAs
(pirNas). rNas approximately 
21–35 nucleotides long 
representing a class of rNas 
that form protein–rNa 
complexes by interacting with 
PiWi proteins. These pirNa 
complexes have been linked to 
the transcriptional silencing of 
retrotransposons and other 
genetic elements in germ line 
cells.
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lipid microdomains (lipid rafts)54. When MVBs fuse 
with the plasma membrane, the intraluminal vesicles 
are released into the extracellular space as exosomes. 
Exosome release relies on the cytoskeleton, such that 
MVBs are transported to the plasma membrane via 
microtubules55, where branched actin, polymerized 
by Arp2/3 and stabilized by the actin- binding protein 
cortactin, supports their docking56. Microvesicles bud 
out from the plasma membrane directly and share many 
of the same proteins involved in exosome biogenesis5,20, 
which makes it challenging to experimentally dissect 
and manipulate the different extracellular vesicle carri-
ers. In addition to these two basic modes of extracellular 
vesicle biogenesis, oncosomes form by blebbing off the 
plasma membrane of tumour cells. These extracellular 
vesicles are usually larger than microvesicles and are 
typically associated with cell motility57–60. Release of 
oncosomes involves recruitment of the actin- bundling 
protein fascin, which together with the actin–plasma 
membrane crosslinker ezrin and the cell- surface glyco-
protein podocalyxin promotes extrusion and scission 
of the plasma membrane29. Other large extracellular 
vesicles, overlapping in size with oncosomes, form 
during apoptotic cell death when plasma membrane 
blebs and spike- like protrusions from the plasma 
membrane (microtubule spikes) break off during 
apoptosis (forming apopto podia)5,60. Finally, some 
extra cellular vesicles can be generated with the engage-
ment of proteins of viral origin, such as retroviral- like 
Gag proteins on the inner plasma membrane that 
bind RNA and bud off from the cell membrane as 
virus- like particles.
During extracellular biogenesis, the cell’s vesiculation 
machinery packages multiple RNA species into differ-
ent subclasses of extracellular vesicles, contributing to 
a substantial portion of the exRNA pool61. Small size, 
high abundance, ability to associate with membranes 
and cytoplasmic (versus nuclear) location favour incor-
poration of a given RNA into extracellular vesicles. Most 
RNAs transit from the nucleus to specific cellular loca-
tions in association with RNA- binding proteins (RBPs), 
which can coalesce into large ribonucleoprotein parti-
cles (containing hundreds of different RNAs and many 
RBPs) that travel along the cytoskeleton62,63. Of note, 
there are more than 500 RBPs in mammalian cells64, 
and RBPs make up about 25% of the protein content 
of extracellular vesicles41. Information is lacking about 
the distribution of these RBPs in different extracellular 
vesicles and their role in loading RNA into these vesicles.
Multiple mechanisms have been implicated in RNA 
packaging into extracellular vesicles, including specific 
RNA sequence motifs and/or secondary configura-
tion65,66, differential affinity for membrane lipids67–69 and 
association with RBPs, such as AGO2 (reF.34), ALIX70, 
annexin A2 (reFs71,72), major vault protein (MVP)73,74, 
HuR75, heterogeneous nuclear ribonucleoproteins A2/B1 
(HNRNPA2B1) (reF.76), YBX1 (reFs77–79), SYNCRIP80,81, 
lupus La protein82 and Arc1 (reF.83) (Fig. 2). Two RBPs, 
heterogeneous nuclear ribonucleoprotein K (HNRNPK) 
and scaffold- attachment factor B1 (SAFB), regulate the 
Y RNAs
small non- coding rNas 
essential for the initiation of 
chromosomal DNa replication. 
When bound to the ro60, 
they are involved in rNa 
stability and cellular responses 
to stress.
Vault RNAs
(vtrNas). small rNa 
components of the vault 
ribonucleoprotein complex. 
approximately 100 
nucleotides in length, they 
function as the intracellular 
and nucleocytoplasmic 
transporters.
Dicer
The rNase iii known as Dicer is 
involved in the cleavage of 
double- stranded rNa and 
microrNa precursor molecules 
forming short double- stranded 
fragments called ‘small 
interfering rNas’ or 
‘microrNas’.
Argonaute
The argonaute protein family 
has a critical role in the 
rNa- induced silencing 
complex. These proteins form 
complexes with microrNas, 
small interfering rNas and 
PiWi- interacting rNas, 
interfering with mrNa 
translation and/or degrading 
target mrNas.
Circular RNAs
single- stranded, non- coding 
rNas that may play a role in 
transcriptional regulation and 
in mediating protein 
interactions. They are 
characterized by a covalently 
closed loop feature without 
5′- end caps or 3′ poly(a) tails.
tRNA fragments
Transfer rNa (trNa)- derived 
fragments are cleaved from 
either mature or precursor 
trNas. Functionally, they can 
act through rNa interference 
pathways, participate in the 
formation of stress granules, 
move mrNa from rNa- binding 
proteins and/or inhibit 
translation.
Multivesicular bodies
(MVbs). represent a late 
endosomal compartment, 
which contains luminal vesicles. 
Vesicles within the MVbs either 
can be degraded when MVbs 
fuse with lysosomes or can be 
secreted as exosomes when 
MVbs fuse with the plasma 
membrane.
Table 2 | challenges and limitations for extracellular vesicle and exrNa research
challenge/limitation consequences Potential solutions
Heterogeneity of extracellular 
vesicles and their (RNA) cargo 
(differences between cell types, 
influence of external conditions, 
additional stimuli, etc.)
Lack of concordance among studies using 
different cell types or biofluid sources
Inability to determine which 
mechanisms/features of extracellular 
vesicle biogenesis and cargo selection are 
universal and which are cell type specific
Inability to precisely manipulate the 
cargo content for improved transfer of 
that content
Systematic studies of extracellular 
vesicle biogenesis and cargo content 
including multiple diverse cell types
Sample- to- sample 
heterogeneity in extracellular 
vesicle and other exRNA carriers
High sample- to- sample technical 
variability that is not related to the 
biological variable of interest
Develop methods to determine the 
relative abundance of each carrier 
subclass in individual samples
Differences (efficiency , purity , 
throughput, etc.) in methods for 
isolating extracellular vesicle 
carriers
Lack of concordance among studies using 
different extracellular vesicle and exRNA 
isolation techniques
Difficulties in determining exRNA activity 
on transfer
Develop methods for unbiased exRNA 
isolation
Establish a comprehensive catalogue 
of extracellular vesicle and 
non- extracellular vesicle exRNA carriers
Develop methods to isolate each 
carrier and characterize its cargo, and 
to perform single- extracellular- vesicle 
cargo analysis
Differences in sensitivity , 
specificity , reproducibility and 
bias for different RNA profiling 
methods
Lack of concordance among studies using 
different exRNA profiling techniques
Develop methods for unbiased exRNA 
profiling
Establish standards that can be used to 
compare sensitivity , specificity and bias 
among methods
exRNA , extracellular RNA.
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small non- coding RNA composition of extracellular 
vesicles via secretory autophagy84. Different RBPs dis-
play binding preferences for different RNA sequence 
motifs, but a full understanding of these binding inter-
actions has yet to be established (see, for example, 
reFs71,76,80,85–87). Other extracellular vesicle sorting sig-
nals may include RNA and/or RBP modifications, such 
as ubiquitylation, sumoylation, phosphorylation and 
uridylation, which also impact RNA splicing, stabil-
ity and translation and miRNA biogenesis88. Exosome 
biogenesis and miRNA- mediated gene silencing may 
be functionally linked89,90. The small GTPase ARF6 
appears to be involved in targeting of pre- miRNAs to 
oncosomes along with miRNA processing machinery29. 
Thus, many mechanisms can influence packaging of 
RNAs into extracellular vesicles, but the extent to which 
these mechanisms are specific to selected RNA species 
and how RNA cargo loading is regulated by the cells 
remain elusive.
Extracellular vesicle RNA delivery
A range of mechanisms have been elucidated for extra-
cellular vesicle uptake by recipient cells; however, what 
dictates how particular cells respond to specific extra-
cellular vesicles remains unknown5. While uptake of ves-
icles is relatively well characterized, more work is needed 
to reveal the mechanisms by which extracellular vesicles 
deliver functional RNA to recipient cells.
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Fig. 2 | rNa packaging into extracellular vesicles and their release into the extracellular space. A variety of different 
RNA species can be packaged into extracellular vesicles. A number of modalities have been proposed for incorporation  
of (specific) RNAs into extracellular vesicles. First, RNAs can be targeted to the plasma membrane and released as 
microvesicles. They can also be targeted to the endosomal compartment and incorporated into intraluminal vesicles (ILVs) 
of the multivesicular body (MVB), which then can be targeted to the plasma membrane, where it fuses to release ILVs as as 
exosomes. Both these modes of biogenesis share many factors, and hence the vesicle type and vesicle origin are typically 
difficult to ascertain and control. Membrane microdomains (lipid rafts) have been strongly associated with the release of 
extracellular vesicles. Also, cytoskeletal components are implicated in extracellular vesicle biogenesis, in particular for 
exosomes, which are transported via microtubules, and their docking at the plasma membrane is supported by Arp2/3- 
generated branched- actin filaments stabilized by the actin- bundling activity of cortactin. Cortical actin remodelling is 
also an important event in membrane shaping during microvesicle release (not shown). Loading of RNA into extracellular 
vesicles can occur via multiple routes: passively due to an abundance of the RNA in the cytosol; by recognition via a 
number of RNA- binding proteins (RBPs), such as Argonaute, annexin A2, major vault protein (MVP), heterogeneous 
nuclear ribonucleoproteins A2/B1 (HNRNPA2B1),YBX1, SYNCRIP and lupus La protein, that bind particular sequence 
motifs in the RNA or that recognize unique secondary RNA structures; and through specific modifications, such as 
uridylation. Packaging of RNA into extracellular vesicles can also be promoted by its recognition by retroviral coat proteins 
such as Gag (and their silent copies present in animal genomes), which efficiently target RNAs they recognize to the 
plasma membrane (or the membrane of the MVB; not shown), resulting in virus- like particle release.
Lipid rafts
subdomains of the plasma 
membrane represented by 
accumulations of proteins and 
lipids, with high concentrations 
of cholesterol and 
glycosphingolipids.
Blebbing
a bulging of the plasma 
membrane accompanied by 
membrane decoupling from 
the underlying cytoskeleton, 
which has the potential to 
release vesicles surrounded by 
the plasma membrane.
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Extracellular vesicle interactions with recipient cells. 
Interaction of extracellular vesicles with recipient cells 
depends on the specific proteins, lipids and glycans on 
their surfaces, as well as their overall negative charge14,91. 
Uptake of extracellular vesicles can be both selective and 
non- specific5,53. For example, extracellular vesicles from 
tumour cells may home to different tissues by virtue of 
the expression of specific integrins on their surface53, 
thereby setting up a tissue- specific niche for incom-
ing metastatic tumour cells4. Once they are in contact 
with recipient cells, multiple routes of extracellular 
vesicle uptake have been reported, including clathrin/
caveolin- mediated endocytosis, macropinocytosis, phago-
cytosis, lipid raft- mediated uptake or direct membrane 
fusion92 (Fig. 3). There are also reports of direct cell- to- 
cell extracellular vesicle transfer via tunnelling nanotubes 
for RNA delivery93–95. The current focus of extracellu-
lar vesicle uptake is on endocytic pathways, which may 
result in part from the difficulty in assessing fusion 
events. Extracellular vesicles may also remain bound 
to cell surfaces without internalization (Fig. 3), engaging 
in cell signalling and antigen presentation53. It is cur-
rently unknown whether cells control the interaction 
and uptake of extracellular vesicles depending on their 
subtype and/or physiological state.
Extracellular vesicle uptake and RNA release into recip-
ient cells. For functional activity of RNAs contained in 
extracellular vesicles within recipient cells, the RNAs 
need to enter the cytoplasm, and if the RNA enter, 
through the endosomal pathway, the RNA must ‘escape’ 
from it (Fig. 3; Supplementary Table 1). Uptake of extra-
cellular vesicles can be promoted at the cell surface. 
For example, binding to heparan sulfate proteoglycans 
on the plasma membrane increased uptake of tumour- 
derived extracellular vesicles via endocytosis96,97, and 
specific integrin receptors can drive selective uptake 
of extracellular vesicles by certain primary tumours98. 
Uptake of extracellular vesicles was also promoted by 
the interaction of T cell immunoglobulin and mucin 
domain- containing protein 4 (TIM4) molecules with 
phosphatidylserine present on extracellular vesicle 
membranes99. Accordingly, these different types of mol-
ecules could be engineered on the surface of extracellular 
vesicles to promote their uptake99.
Importantly, extracellular vesicle uptake through the 
endosomal and engulfment (phagocytosis and macro-
pinocytosis) pathways poses challenges to delivery of 
functional RNA into the cytoplasm, as a prominent role 
of these pathways is to shuttle cargo to the lysosome 
for degradation100. Indeed, it has been demonstrated 
that despite successful uptake, generation of functional 
protein from extracellular vesicle- derived mRNA in 
recipient cells was negligible, suggesting that endoso-
mal escape is critical to RNA function101. It is possible 
that extracellular vesicles might naturally incorporate 
some mechanisms for endosomal escape, which so far 
remain unknown. Nevertheless, establishing reliable 
means of increasing the efficiency of extracellular vesi-
cle cargo escape from the endosomal compartment will 
likely be essential to widen the application potential of 
extracellular vesicles (see also later).
Progress on understanding extracellular vesicle cargo 
delivery to recipient cells has been hampered by the lack 
of sensitive and specific markers for optical and mole-
cular tracking. Protein delivery can be monitored by 
use of a GFP–luciferase dual split tag with a fluorescent 
and bioluminescent readout when extracellular vesicle 
cargo is united with its other half in the cytosol102. Tools 
developed for tracking of nanoparticles, liposomes and 
viruses may prove useful in elucidating these mecha-
nisms (Table 3; Supplementary Table 1). RNA cargo 
delivery could be facilitated by use of recipient cells null 
for the RNA being tracked, but this experimental mani-
pulation might alter the cell phenotype, thereby skewing 
interpretation3,103.
Biology of extracellular vesicle RNA
Once the extracellular vesicle RNA cargo has been deliv-
ered to the recipient cell and has escaped the degradative 
pathway, it may elicit a functional response. Among the 
various RNA biotypes present in extracellular vesicles, 
most is known about miRNAs as mediators of cell–
cell communication, with more limited information 
on the functions of other RNA biotypes. Several dif-
ficulties arise in establishing the functionality of RNA 
in extra cellular vesicles. First, overexpression systems 
that increase the amounts of a particular RNA in extra-
cellular vesicles can result in supraphysiological levels of 
the RNA in source cells, potentially resulting in changes 
in the extracellular vesicle release process and/or altering 
levels of other cargo. Functional effects of the RNA cargo 
of interest may be affected by the other cargo delivered 
at the same time. The population of exRNAs — impor-
tantly RNA in extracellular vesicles — in conditioned 
cell culture medium is highly dependent on the culture 
methods used. Most prominently, bovine serum, which 
is widely used as a medium supplement, contains bovine 
RNA in extracellular vesicles and non- vesicular entities. 
These exRNAs can confound molecular and functional 
readouts in the extracellular vesicle- recipient cell, parti-
cularly as many miRNAs are highly conserved among 
mammalian species104. Methods to remove exRNAs from 
bovine serum through ultracentrifugation or affinity 
purification result in partial, but not complete, deple-
tion12,13. Another confounding problem is mycoplasma 
infection of cell cultures105, and this must be monitored 
frequently.
Extracellular vesicle RNA cargoes can be divided on 
the basis of knowledge of their bioactivity into those with 
known functions, those with predicted functions and 
those with unknown functions (Fig. 1), with the third cat-
egory evoking the early concept of extra cellular vesicles 
as disposal units for some molecules16,106. Nevertheless, 
even when used as a means for discarding, RNA may 
have functional effects on both donor and recipient cells. 
Several prominent examples of functional effects for dif-
ferent species of extracellular vesicle RNA are discussed 
in the following sections.
miRNAs. Numerous examples of extracellular vesicle- 
mediated functional transfer of miRNAs have been 
demonstrated with use of both in vitro and in vivo 
models for a variety of diseases and physiological 
Secretory autophagy
The transportation of proteins 
via the autophagosome to the 
plasma membrane, 
multivesicular bodies or 
secretory lysosomes resulting 
in extracellular release of 
proteins.
Macropinocytosis
an endocytic process that 
results in the cellular uptake of 
fluid and particles less than 
0.2 μm in diameter via 
invaginated membranes that 
then form intracellular vesicles.
Tunnelling nanotubes
Dynamic actin- driven 
protrusions from the plasma 
membrane of cells that form 
connections between cells 
more than 100 μm away to 
facilitate intercellular 
communication.
Proteoglycans
Highly glycosylated proteins 
that form the major component 
of the extracellular matrix. 
glycosaminoglycans of 
proteoglycans are divided into 
seven main classes: hyaluronic 
acid, chondroitin sulfate a, 
chondroitin sulfate b, 
chondroitin sulfate C, keratan 
sulfate i, keratan sulfate ii and 
heparin. Proteoglycans act as 
molecular filters, regulating 
movement of macromolecules, 
such as albumin and 
immunoglobulins, throughout 
the matrix.
Liposomes
small spherical nanoparticles 
that contain an aqueous core 
solution and at least one 
phospholipid bilayer. They can 
be prepared from biological 
membranes and are often used 
for drug delivery.
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states with a broad range of downstream effects. For 
example, miR-193b is secreted via extracellular vesi-
cles in the central nervous system and decreases levels 
of amyloid precursor protein in neuronal cells, provid-
ing reductions in the pathology of Alzheimer dis-
ease, and the content of this miRNA in extracellular 
vesicles can be used as a biomarker for this disease107. 
In other examples in the nervous system, neurons pro-
duce miR-124a- loaded extracellular vesicles that regu-
late the glutamate transporter in astrocytes, which is 
important for synaptic transmission108. In the context 
of brain cancer, astrocytes secrete extracellular vesi-
cles with miR-19, which inhibits an important tumour 
suppressor, PTEN, in cancer cells, thereby promot-
ing growth of brain metastases109. As another exam-
ple, extracellular vesicles from mesenchymal stem cells 
enriched in miR-375 via its overexpression stimulated 
bone regeneration by bone marrow stem cells110. Two 
critical miRNAs that regulate inflammation, miR-155 
and miR-146a, are exchanged between dendritic 
cells in vivo, with the latter inhibiting and the for-
mer promoting endotoxin- induced inflammation in 
mice111. Other recent examples of transfer of functional 
miRNAs by extracellular vesicles from cancer, cardiac, 
neural, immune and adipose cells are summarized 
in Table 1.
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Amyloid precursor protein
a transmembrane protein that 
is a precursor of β- amyloid, a 
protein involved in the 
pathology of alzheimer 
disease.
Mesenchymal stem cells
Multipotent stromal progenitor 
cells found in a number of 
different tissues that are 
capable of self- renewal and 
differentiation into a variety of 
cell types.
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mRNAs. Most full- length mRNAs in extracellular vesi-
cles are smaller than 1 kb (reF.112), but clearly, in analogy 
to retroviruses, longer RNA sequences could be incorpo-
rated in a condensed configuration113. mRNAs in extra-
cellular vesicles could serve as a source of novel proteins 
in recipient cells. Exit from the endosome could be a 
bottleneck in functional mRNA delivery101 and may 
depend on the donor and/or recipient cell types. How-
ever, active translation of mRNAs transported by extra-
cellular vesicles into recipient cells was reported early 
on; for example, expression of reporter proteins from 
mRNA transferred by extracellular vesicles between 
mast cells23 and from glioblastoma to endo thelial cells24. 
In one study mRNAs transported within extracellular 
vesicles were translated within 1 hour after extracellu-
lar vesicle uptake during bidirectional exchange in co- 
cultures of glioblastoma and HEK293T cells114. There 
is also evidence that extracellular vesicle mRNA can 
generate active proteins, as transfer of Cre recombinase 
mRNA in extracellular vesicles led to recombination 
events in the brains of floxed reporter mice115,116. Of 
note, this study analysed the extracellular vesicles for 
Cre mRNA and protein, and while the former was dete-
cted by reverse transcription–PCR, the latter was not 
detected by western blot or enzyme- linked immuno-
sorbent assay. But because reverse transcription–PCR 
is markedly more sensitive than either of the last two 
protein detection techniques, the contribution of the 
extracellular vesicle- mediated protein transfer of Cre to 
this functional effect cannot be ruled out. Extracellular 
vesicle- mediated transfer of mRNAs between human 
pulmonary artery smooth muscle cells (stimulated by 
transforming growth factor- β) and arterial endothelial 
cells has also been demonstrated with a number of dif-
ferent mRNAs present in these extracellular vesicles, 
prominently including regulators of the actin cytoskel-
eton and extracellular matrix remodelling117. Because 
transforming growth factor- β is a cytokine relevant for 
the pathology of pulmonary arterial hypertension, this 
extracellular vesicle- mediated communication could be 
involved in the disease phenotype117.
Importantly, as extracellular vesicles typically carry 
both the mRNA and its encoded protein, it is difficult to 
distinguish newly translated protein in recipient cells. 
Changing the experimental paradigm revealed that 
delivery of human erythropoietin mRNA to cells via 
lipid nanoparticles resulted in release of extracellular 
vesicles containing the mRNA, which was then trans-
lated in mouse cells118. Extracellular vesicles derived 
from human red blood cells have also been loaded 
with mRNA for Cas9 by electroporation (see more 
details later) and used for CRISPR editing in recipi-
ent cells119. These studies establish that indeed mRNA 
delivered by extracellular vesicles can be translated in 
recipient cells.
lncRNAs. The functions of lncRNAs (longer than 200 bp) 
are diverse, ranging from negative regulation of miRNAs 
by serving as miRNA ‘sponges’120,121 to marking of 
mRNAs for degradation122 and transcriptional regu-
lation of genes123. Several studies implicate the role of 
extracellular vesicle- transferred lncRNAs in biological 
processes. One recent study documented that hypoxic 
cardiomyocytes release extracellular vesicles with high 
levels of lncRNA NEAT1, which taken up by fibroblasts 
induces a profibrotic gene expression programme124. 
In another study, incorporation of hypoxia- inducible 
factor 1α- stabilizing lncRNA into extracellular vesicles 
released by tumour- associated macrophages supported 
breast cancer cell viability125. A future challenge will be 
determining the mechanism of action of these and other 
lncRNAs in extracellular vesicles.
tRNA fragments. Next to miRNAs, tRNA fragments are 
the most abundant small non- coding RNAs in extra-
cellular vesicles. These species function in the regula-
tion of gene expression and epigenetics, particularly in 
the context of immunomodulation47 and cancer pro-
gression126,127. Extracellular vesicles contain different 
sets of tRNA fragments that can be enriched, as shown 
for T cells, where 45% of these species were 1.5- fold 
enriched in extracellular vesicles compared with whole 
cells47. Specific tRNA fragments derived from the same 
tRNA are sorted into extracellular vesicles, while others 
are not. The tRNA fragment content of extracellular ves-
icles appears to be dependent on the source cell state, as 
for T cell activation, which results in changes in the types 
of tRNA fragments incorporated into extracellular vesi-
cles, with some fragments showing activation- dependent 
sorting into extracellular vesicles47. Silencing of these 
activation- dependent tRNA fragments promoted T cell 
activation, suggesting that in this case, secretion of tRNA 
fragments is a means of removing them from the cell, 
thereby preventing repression of immune responses47. 
Whether tRNAs and their fragments in extracellular ves-
icles have functional effects in recipient cells remains to 
be established.
Fig. 3 | extracellular vesicle rNa cargo interaction with recipient cells and its 
functional delivery. After encountering the recipient cell, the extracellular vesicle is 
typically bound to its surface via cell- surface receptors (although extracellular vesicles 
can also be engulfed from the environment in a process known as macropinocytosis; not 
shown). After establishing an interaction with the cell surface, the vesicle can remain 
bound on the surface or can be internalized (1). One possible means of internalization is 
direct fusion with the plasma membrane (2), but the most common mechanism of 
internalization involves endocytosis, whereby extracellular vesicles are taken up to 
endosomes (3). In the endosome, RNA content might be released into the luminal space 
(if the integrity of the extracellular vesicle membrane is perturbed) or it might be 
released into the cytoplasm (of note, the frequency of these events is low , and endosomal 
escape of extracellular vesicle cargo is currently an important bottleneck in functional 
RNA cargo delivery by extracellular vesicles). In both cases RNAs can be recognized by 
pattern recognition receptors, such as Toll- like receptors (TLRs) and RIG- I or NOD- like 
receptors that reside in the endosome and in the cytoplasm, respectively , raising innate 
immune response signalling (4). Early endosomes will gradually transform into late 
endosomes with progressive internal acidification and possible release of RNA 
(stimulated by the decreasing pH) (5). Further down the endocytic pathway , endosomes 
will mature into lysosomes, in which the cargo that has not been released to the 
cytoplasm will be degraded (6). RNA cargo that reaches the cytoplasm can elicit its 
functional effect. For example, mRNA can be translated into a functional protein, such as 
green fluorescent protein (GFP), and the resulting fluorescence can act as a reporter of 
functional delivery of extracellular vesicle cargo (7). When small interfering RNA (siRNA) 
cargo is released into the cytoplasm, it can inhibit translation of specific transcripts, such 
as those encoding fluorescent proteins. In this case, disappearance of fluorescence will 
report on functional delivery of extracellular vesicle cargo (8). Extracellular vesicles can 
be tracked along this route with use of different reagents or labelling strategies (Table 3). 
5′ppp- RNA , 5′- triphosphorylated RNA.
Cre recombinase
a type i topoisomerase from 
bacteriophage P1 that 
catalyses cleavage and ligation 
of DNa at specific loxP 
recognition sites.
◀
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Table 3 | approaches for extracellular vesicle tracking
Purpose of labelling reagent/approach Description refs
Visualizing extracellular vesicles
Membrane labelling DiI, DiD, DiR , DiO Lipophilic carbocyanines. Incubating donor/recipient cells with DiD labels lipid 
membrane via lateral diffusion
268
CellMask Amphipathic molecule with a lipophilic moiety and a negatively charged hydrophilic 
dye that anchors the probe in the membrane. Incubation of donor/recipient cells 
with this dye results in membrane labelling
248
FM 4-64, FM 1-43 Lipophilic styryl compound. Incubating donor/recipient cells with this dye allows the 
dye to enter the outer leaflet of the surface membrane
269
PKH26, PKH67 , PKH2 Aliphatic molecules incorporated via selective partitioning into lipid membrane (of 
note, PKH26 can aggregate into particles, causing artefacts or false positive signals)
270
Antibody- based tracking of 
extracellular vesicles
Use of Alexa Fluor- conjugated antibodies indirectly binding the extracellular vesicle 
proteins TSG101, CD63 and HSP70, allowing visualization of extracellular vesicles 
with fluorescent confocal microscopy or super- resolution microscopy
271
Membrane labelling of 
extracellular vesicles with 
fluorescent protein
Palmitoylation signal placed in- frame of the N terminus of fluorescent protein 114
Reporter tagging of 
transmembrane extracellular 
vesicle markers
Extracellular vesicle- associated proteins, such as flotillin 1, flotillin2, RAB5, RAB7 and 
CD63, can be conjugated to fluorescent proteins such as GFP and mCherry. In this way 
extracellular vesicles can be imaged intracellularly with time- lapse confocal imaging
272
Vesicle interior 
labelling  
(cell/extracellular 
vesicle- encapsulated 
dyes)
Carboxyfluorescein 
diacetate succinimidyl ester
A cell- permeable dye that labels intracellular molecules by covalently binding to 
intracellular lysine residues and other amine sources
273
Calcein AM A compound hydrolysed by intracellular esterases resulting in fluorescent signal 
retained within the cell
274
CellTracker CM- Dil Conjugates to thiol- containing peptides and proteins, retaining the fluorescent 
signal within the cell
275
Labelling RNA cargo Alexa- labelled RNA Dye that forms a stable complex with particular nucleic acids 276
TAMRA NHS Dye that forms a covalent amide bond with primary amine group 269
SYTO RNASelect Green Cell- permeant nucleic acid stains 35
Monitoring extracellular vesicle uptake
Monitoring fusion Quenching assays (BODIPY, 
NBD–rhodamine assays, 
octadecyl rhodamine B 
self- quenching)
Dyes with FRET- based self- quenching. Before fusion the probe dimer is 
self- quenched owing to close proximity. On fusion with a larger membrane (for 
example, plasma membrane or endosome) the dimer is separated and therefore no 
longer quenched, releasing a fluorescent signal. Therefore, detection of a fluorescent 
signal indicates fusion/uptake of extracellular vesicle content
277–279
Pyrene excimer formation Pyrene labelling lipids. Lipid probes labelled with pyrene that form dimers emit 
red- shifted fluorescence but when mixed with non- labelled lipids the dimer 
fluorescence is replaced by monomer blue- shifted fluorescence
280
Monitoring pH 
changes (indicating 
endosomal uptake)
pHluorin pH sensitive variant of GFP 281
pHRodo Fluorogenic pH- sensitive dye 215
Organelle labelling Fluorescently fused proteins Fluorescent protein tagged to organelle- associated proteins EEA1 (early endosome), 
RAB5 (early/mobile endosome) and RAB7 (maturation to late endosome). Visual 
tracking of each compartment allows tracking of vesicles within endosomal pathway 
as well as visualization of escape from the endosomal pathway
276
LysoTracker Fluorophore linked to weak base. Labels endolysosomal compartment, allowing 
tracking of extracellular vesicles to the lysosome or visualization of a separation of 
extracellular vesicles from the endosomal pathway
282
Monitoring functional output
Visualizing cytosolic 
release
β- Lactamase assay CCF2- AM is a FRET substrate that is hydrolysed by the enzyme β- lactamase, producing 
a coloured product that is directly proportional to enzyme activity. Delivery of the 
enzyme (via a virus/extracellular vesicle) to a recipient cell expressing CCF2- AM 
results in a detectable fluorescent signal as a consequence of cytosolic release
283
Split protein assay 
(luminescent/fluorescent)
Re- formation of separated protein fragments results in a signal. This confirms uptake 
of extracellular vesicle content whereby one fragment is present in extracellular 
vesicles and the complementary fragment is expressed in the recipient cell
284
Evidencing mRNA 
translation with reporter 
mRNA
Exemplified by the use of reporter mRNA encoding Gaussia luciferase. Translation 
is evidenced by the signal from the reporter assay , which is prevented by treatment 
with the translation inhibitor cycloheximide
114
FRET, fluorescence resonance energy transfer; NBD, 7- nitro-2,1,3- benzoxadiazoI-4- yl.
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snoRNAs. The main function of snoRNAs is to guide 
chemical modification of other RNA species. snoRNAs 
are enriched in extracellular vesicles compared with 
the source cell, and after entry into recipient cells, they 
are shuttled to the nucleus. The snoRNA content of 
extra cellular vesicles is influenced by the biological 
state of the source cell and has been shown to change 
in immune cells, such as dendritic cells treated with 
immuno repressive or immunostimulatory factors128, 
and in activated macrophages129. In the latter case, these 
extracellular vesicles were taken up by distant cells with 
an associated increase in 2′- O- methylation of RNA — a 
modification that the snoRNAs released by the macro-
phages direct on their canonical rRNA targets. Hence, 
extracellular vesicle-derived snoRNAs can be modulators 
of inflammation.
ncRNAs signalling via cellular receptors. In addition 
to their more specific functions, extracellular vesicle- 
associated ncRNAs can also produce effects via direct 
interactions with cytoplasmic receptors, in particu-
lar immune receptors, such as rig- i- like receptors, 
which recognize pathogen- associated molecular 
patterns (PAMPs), and the NoD- like receptor family, 
which in addition to PAMPs also recognizes endoge-
nously derived damage- associated molecular patterns 
(DAMPs). Most of what we know about how exRNA 
triggers these cytoplasmic receptors has been revealed 
for extracellular vesicles carrying microbial content130. 
For example, Mycobacterium tuberculosis RNA is 
packed into extracellular vesicles released from infec-
ted macrophages that are subsequently taken up by 
other macrophages. This triggers the RIG- I RNA sens-
ing pathway leading to production of type i interferon 
and accelerated maturation of bacteria- containing 
phagosomes by recipient macrophages, supporting 
increased bacterial killing131. A similar mechanism is 
used during latent infection with Epstein–Barr virus, 
whereby infected B cells release extracellular vesicles 
containing viral ncRNAs with the potential to stimulate 
RIG- I and other related PAMP receptors. These extra-
cellular vesicles act on dendritic cells and stimulate anti-
viral responses132. There are also hints in the literature 
that some mammalian RNAs are able to trigger these 
receptor- mediated pathways. For example, cancer stro-
mal fibroblasts increase the expression of RN7SL1 — an 
endogenous 5′- triphosphorylated RNA (representing 
a canonical target for RIG- I) — which is normally 
shielded by binding to its RBP. This increased expres-
sion results in unshielded RN7SL1, which is packaged 
into extracellular vesicles and when delivered to breast 
cancer cells induces RIG- I signalling and interferon- 
stimulated gene expression, resulting in cancer promo-
tion133 and therapy resistance134. However, it is worth 
noting that in addition to these signalling responses 
to exRNA, any exogenous RNA may be perceived as 
‘foreign’ by the recipient cell, leading to RIG- mediated 
degradation135. In addition to proactive effects of RIG- I 
signalling in infection and cancer, recognition of 
exRNA by immune receptors can also lead to patho-
logical inflammation and rejection of recipient cells by 
the activation of the immune system.
In addition to immune receptors, some exRNAs are 
recognized by autophagy receptors in the cytoplasm. 
For example, vtRNAs present in extracellular vesicles27 
as well as in ribonucleoprotein particles136 can serve as 
important regulators of autophagy. They bind directly 
to the intracellular autophagy receptor sequestosome 1 
(also known as p62), thereby interfering with oligomer-
ization of the receptor and downstream clearance of 
protein aggregates through the autophagic pathway137. 
However, the presence of vtRNA in extracellular vesicles 
has been challenged recently by a study showing that 
vtRNA was restricted to the non- vesicular exRNA in a 
human colon cancer cell line and was present only as 
a minor component in small extracellular vesicles in a 
human glioma line10. This discrepancy may relate to the 
way the vesicles were isolated in the different studies or 
to differences in the cells of origin (non- transformed 
cells versus cancer cells).
Many of the small RNAs in extracellular vesicles have 
the potential to influence recipient cells even without 
reaching the cytoplasm. These exRNAs can potentially 
trigger Toll- like receptors (TLRs) and thereby elicit an 
innate immune response106. The most likely TLRs for 
this task are TLR3, TLR7, TLR8 and TLR9, which are 
intrinsically capable of sensing PAMPs and DAMPs and 
operate within the endosomal compartment during 
its maturation and acidification138. If the lipid layer of 
extracellular vesicles surrounding the cargo is breached 
after endocytosis, the RNA cargo could be exposed 
inside the endosome. As such, TLRs in the endosome 
of the recipient cells could be triggered by recognizing 
this single- stranded RNA cargo. This has been demon-
strated for miR-21 and miR-29a, which are secreted by 
lung cancer cells within extracellular vesicles, which are 
then taken up by surrounding immune cells in vivo and 
activate endosomal TLR7 and TLR8, thereby inducing 
a proinflammatory phenotype that supports cancer 
progression139. Similarly, members of the let-7 miRNA 
family (let-7a and let-7e) in extracellular vesicles140,141 
harbour a specific GU- rich motif (GUUGUGU) that 
binds to and activates TLR7. TLR7 activation could, in 
turn, impact cell function in disease- relevant contexts, 
including neurodegeneration142 and cancer143.
Extracellular vesicles in viral transfer. Nucleic acids of 
intracellular pathogens can also be packaged into extra-
cellular vesicles in infected cells and trigger protective 
responses in surrounding cells. In some cases, extra-
cellular vesicles can also be co- opted into facilitating viral 
RNA transfer and, as such, aid in viral functions. Non- 
enveloped RNA viruses, such as leishmania RNA virus 1, 
hepatitis A virus and hepatitis C virus can be packaged 
into extracellular vesicles, serving as an invisibility cloak 
to shield them from host immune surveillance144–146. 
Some viral proteins are specialized in the transmission 
of viral RNA via extracellular vesicle subspecies that 
contain elements of both the plasma membrane and the 
viral envelope. Intriguing reports raise the possibility 
that even without viral proteins, extracellular vesicles 
can transport functional hepatitis C virus RNA between 
cells in a virion- independent manner147,148. Similarly, the 
retrovirus- derived Gag protein ARC encoded in fly83 and 
RIG- I- like receptors
intracellular pattern 
recognition receptors that 
belong to the rNa box helicase 
family that function as 
cytoplasmic sensors of 
pathogen- associated molecular 
patterns elicited by viral rNa.
NOD- like receptor family
Cytoplasmic receptors 
expressed by innate immune 
and other cells. They are part 
of the family of intracellular 
pattern recognition receptors 
and can recognize structures 
associated with pathogenic 
microorganisms (pathogen- 
associated molecular patterns) 
or with cell damage 
(damage- associated molecular 
patterns), thereby activating 
the innate immune response 
and inflammation.
Type I interferon
a large subgroup of cytokines 
that help to regulate the 
activity of the immune system. 
They act to degrade viral DNa 
and proteins in infected cells 
and provide protection to 
surrounding cells through 
interaction with and signalling 
from interferon receptors.
Toll- like receptors
(Tlrs). a class of 
transmembrane proteins 
involved in the defence of the 
organism through innate 
immunity. They are mainly 
expressed on the membrane of 
sentinel cells, such as 
macrophages and dendritic 
cells, and recognize certain 
typical structures of pathogens 
and microorganisms.
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mammalian149 genomes can form and release enveloped 
capsids that contain their own mRNA (about 1 kb). The 
trans- synaptic delivery of these extracellular vesicles 
between neurons and expression of the encoded ARC 
RNA in postsynaptic neurons were found to be critical 
in modulating synaptic plasticity.
Modulating RNA cargo and its delivery
Incorporating selected RNA cargo into extracellular 
vesicles with the potential for targeting to specific cell 
types in vivo has immense therapeutic potential. One 
important issue in functional extracellular vesicle trans-
fer is the type of cells the vesicles are obtained from. 
Depending on the clinical use, cell sources include 
mesenchymal stem cells, which can be isolated from a 
number of different tissues and are intrinsically regen-
erative and non- inflammatory150,151; red blood cells of 
type O donors, which are easily loaded with cargo152; and 
dendritic cells, which can present antigens and activate 
T lymphocytes and thus be used for vaccination153,154. 
In the last context, extracellular vesicles from tumour 
cells could be used to elicit antitumour immune res-
ponses via presentation of tumour- associated antigens. 
However, there is concern that vesicles isolated from 
immortalized cells or tumour cells may carry oncogenic 
factors and contribute to cancer155.
As mentioned earlier, extracellular vesicles have 
many similarities to enveloped viruses, which can serve 
as prototypes to understand the potential for these ves-
icles to act as vectors for delivery of functional RNAs. 
Enveloped coronaviruses, for example, have a size sim-
ilar to that of extracellular vesicles (125 nm) and con-
tain single- stranded RNA of up to 30 kb. This is the 
largest reported genome size of any RNA virus and may 
serve as a benchmark for the maximum RNA capacity 
of these vesicles when packaged in a condensed form. 
Nevertheless, in addition to RNA, extracellular ves-
icles contain many other types of cargo, which might 
have to be displaced to allow full RNA- loading capac-
ity. Different approaches are being explored for loading 
RNA into extracellular vesicles, targeting strategies and 
production considerations.
Packaging selected RNA into extracellular vesicles. 
Loading of the desired cargo for transfer via extra-
cellular vesicles can be achieved either endogenously, 
by modulation of the donor cell to favour inclusion of 
the selected cargo into extracellular vesicles, or exoge-
nously, in which case the cargo is loaded into isolated 
extracellular vesicles in vitro.
In endogenous loading, overexpression of an RNA 
in the source cell through DNA transfection or lenti-
viral transduction usually results in enrichment of 
that RNA, as well as any encoded protein, in the extra-
cellular vesicles generated by those cells156,157. The yield 
of RNA- loaded extracellular vesicles can be further 
increased by mechanical extrusion of vesicles through 
a micrometre- pore- sized filter using cells that express 
high levels of the desired mRNA158. RNA enrichment 
can also be achieved by having the donor cells express 
a protein that both interacts with the plasma mem-
brane (for example, via different lipid anchors)159 or 
a viral envelope protein (such as vesicular stomatitis 
virus glycoprotein)101 and has an RNA- binding motif, 
typically of viral origin (for example, the RNA- binding 
peptide from the MS2 bacteriophage coat protein)160. 
In concert, the cargo RNA is equipped with specific 
sequences recognized by the RNA- binding motif in 
the protein, allowing targeting of the RNA of interest 
to the plasma membrane and facilitating its release 
through budding from the plasma membrane, mim-
icking retrovirus- like particle release159 (Fig. 2). It is 
also possible to target RNAs to MVBs, by expressing 
protein fusions that couple an MVB- enriched pro-
tein (such as lysosome- associated membrane protein 2, 
tetraspanin or CD63) with an RNA- binding motif101,161. 
One approach for selective enrichment in extracellular 
vesicles took advantage of a specific subpopulation of 
microvesicles, referred to as ‘arrestin domain- containing 
protein 1 (ARRDC1)- mediated microvesicles’. In this 
approach, ARRDC1 and RNA cargo were engineered 
to interact — via including the transactivator of tran-
scription (Tat) peptide from HIV in ARRDC1 and its 
RNA binding- motif, transactivating response (TAR) 
element, in the RNA — allowing efficient generation 
of RNA cargo- loaded extracellular vesicles. This strat-
egy was successful in transfer of p53 mRNA, which was 
translated in recipient cells on uptake (including in vivo 
delivery into mice)162. Beyond the use of viral compo-
nents, other approaches have included incorporation 
of ‘zipcode’ sequences, typically in the 3′ untranslated 
region of the cargo RNA, which can be recognized by 
specific RBPs associated with membrane- targeted or 
MVB- targeted proteins (see, for example, reFs85,161). 
Taking advantage of the lipid biocomposition of extra-
cellular vesicles can also help in loading RNA–RBP 
complexes into them, by engineering RBPs to bind 
to extracellular vesicle membranes more efficiently 
via addition of specific peptides. The different lipids 
in extracellular vesicles make possible binding with 
curvature- sensing and lipid composition- specific affin-
ity peptides. Annexin A5 is a well- known example that 
binds to negative curvature- specific lipid phosphatidyl-
serine on apoptotic bodies and extracellular vesicles, 
while the effective domain (residues 151–175) of myris-
toylated alanine- rich C- kinase substrate (MARCKS) 
protein has an affinity for positive- curvature- associated 
lipid, phosphatidylinositol 4,5- bisphosphate that is 
present on plasma membrane- derived vesicles163. Some 
other proteins, such as bradykinin, can also harbour 
peptides that bind highly curved membranes164. Other 
options include incorporation of binding domains 
of proteins with affinity for intracellular membranes, 
such as phosphatidylinositol 4,5- bisphosphate or 
phosphatidylinositol 3,4,5- trisphosphate159.
Common methods to load RNA into isolated extra-
cellular vesicles exogenously include electroporation of 
siRNAs (see, for example, reFs119,165–169), antisense oligo-
nucleotides119 and mRNAs119, as well as use of sonica-
tion170 and lipofectamine169. One of the most promising 
approaches uses chemically stabilized siRNAs bearing a 
lipophilic moiety, such as cholesterol, which results in 
high incorporation onto and through the lipid mem-
brane of the extracellular vesicles with documented 
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functional knockdown of target mRNA in vivo171,172. 
Still, it is important to keep in mind that isolated extra-
cellular vesicles are inherently already ‘full’ of RNA and 
proteins, and it is not clear how much more additional 
cargo can be effectively loaded into them. Nevertheless, 
the lipid membrane may be extendable, and stabilized 
siRNAs can be loaded on both the inside and the out-
side, thereby supporting these in vitro loading strategies. 
In considering different modes of loading of RNA into 
isolated extracellular vesicles, one should also keep in 
mind the integrity of the vesicles and potential antigenic/
toxic components included in the loading process, which 
may limit successive administrations of exogenously 
loaded vesicles.
Strategies to control extracellular vesicle yield and 
stability. In addition to cargo loading, to ensure efficient 
cell–cell communication (especially in a therapeutic 
setting), it is key to ensure high yields of high- quality 
extracellular vesicle production173. Generally, obtaining 
large amounts of pure extracellular vesicle preparations 
necessitates copious starting material, and enhancing 
the production of extracellular vesicles is a current focus 
of many researchers and biotechnology companies. 
Increasing extracellular vesicle biogenesis in the donor 
cell is one strategy to increase the overall availability of 
extracellular vesicle RNA. One possibility is to overex-
press regulatory proteins involved in extracellular vesicle 
biogenesis. A screen with a readout for the numbers of 
extracellular vesicles released identified factors in the 
donor cell that promoted exosome biogenesis, including 
STEAP3 (involved in exosome biogenesis), syndecan 4 
(MVB formation) and an increase in the citric acid cycle 
to boost production of RNA cargo- loaded exosomes161. 
In another study, overexpression of the actin- bundling 
protein cortactin to increase MVB docking at the plasma 
membrane (see Fig. 2) proved efficient in increasing 
exosome release56. Treatment of source cells with dif-
ferent compounds, such as bafilomycin A1 (a V- aTPase 
inhibitor174) or heparanase175, which regulates secre-
tion, composition and function of tumour cell- derived 
exosomes, also increased production of extracellular ves-
icles. Extracellular vesicle secretion was also increased 
by elevated levels of intracellular Ca2+ in response to 
treatment with monesin, a Na+/H+ exchanger176. Natural 
compounds can influence extracellular vesicle release; 
for example, microglia exposed to serotonin exhibited 
increased fusion of MVBs with the plasma membrane, 
via increase in cytosolic Ca2+ concentration177. Radiation, 
hypoxia, oxidative stress and low pH can all upregulate 
extracellular vesicle production178–181. Vesicular stomati-
tis virus glycoprotein also promotes extracellular vesicle 
release182,183. Finally, the yield of isolated extracellular 
vesicles can be increased by in vitro fusion with syn-
thetic lipids, followed by extrusion though small pores 
(100–400 nm in diameter184). These vesicles could then 
be loaded with cargo (siRNA) via electroporation and 
were successfully taken up by recipient cells in culture 
at a rate that was more than tenfold higher than that of 
native vesicles184.
Although increased production of extracellular 
vesicles is generally desired for therapeutic purposes, 
inhibition of extracellular vesicle release from tumour 
cells has been proposed as a therapeutic strategy to 
curtail advancement of cancer. A number of com-
pounds have been identified that reduce secretion of 
extracellular vesicles. For example, the antihistamine 
drug ketotifen185 and the antibiotic sulfisoxazole186 curb 
extracellular vesicle release in multiple cancer cell lines. 
Screens for modulators of extracellular vesicle secretion 
have yielded various chemical compounds that both 
increase secretion (for example, sitafloxacin, chloroin-
dole and fenoterol) and reduce secretion (for example, 
manumycin A, tipifarnib and neticonazole)187. In a dif-
ferent approach, breast cancer- derived exosomes were 
removed from the circulation through extracorporeal 
haemofiltration in an attempt to decrease growth of 
breast cancer in patients188.
Despite the progress in regulating extracellular vesi-
cle production and loading of cargo, many of the strat-
egies in place so far use treatments that may alter cell 
phenotypes and extracellular vesicle functionality and/or 
have a toxic or immunogenic response in vivo. Further 
work will be needed to expand and evaluate these 
methods for research and clinical use.
Targeting extracellular vesicles to specific cell types and 
promoting uptake. Similarly to viral gene therapy, a major 
challenge in using extracellular vesicles for therapeutic 
purposes is achieving delivery to diseased cells in living 
organisms. Extracellular vesicles administered in vivo 
suffer from rapid clearance mostly by uptake into cells 
in the liver, kidneys, lungs and spleen189–191 with differ-
ent routes of administration, including intravascular, 
intraperitoneal and subcutaneous, altering the distri-
bution only to a minor extent191. Overall, goals include 
increased targeting of therapeutic extracellular vesicles 
to specific cell types, facilitation of their translocation 
through different biological barriers and extending the 
half- life of vesicles in extracellular spaces in vivo. Some 
increase in stability in vivo has been achieved by coating 
extracellular vesicles with the synthetic polymer poly-
ethylene glycol192 or displaying CD47 on their surface, 
which decreases phagocytosis by macrophages168.
More selective targeting to tissues/cells of interest 
could be achieved by the incorporation of specific ligands 
on the surface of extracellular vesicles, including pro-
teins/peptides, antibodies, lipid- associated entities and 
rNa aptamers193 that will be recognized by the acceptor 
cell (for a review, see reF.90). In an early attempt to route 
extracellular vesicles to the brain after intravenous deliv-
ery, a peptide from rabies virus glycoprotein that targets 
acetylcholine receptor- expressing cells in the brain was 
fused to lysosome- associated membrane protein 2B 
(which associates with MVBs)165, but its effectiveness dif-
fers in different studies. Extracellular vesicles have also 
been engineered to display a nanobody to the epidermal 
growth factor receptor on their surface to target tumour 
cells expressing this receptor194. Tissue- targeting ligands 
can also be linked to the phosphatidylserine- binding 
domain of lactadherin, which is exposed on the sur-
face of extracellular vesicles195. In yet another approach, 
a single- chain variable fragment of an anti- HIV mono-
clonal antibody was incorporated into an expression 
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vector designed to target recombinant proteins to the 
surface of mammalian cells to deliver apoptosis- inducing 
miR-143 (or the drug curcumin) to kill HIV- infected 
cells196. Finally, a high- throughput screening method 
(phage display) was used to identify a peptide, CP05, 
that binds to an extracellular domain of tetraspanin 
CD63 (reF.197). By linking muscle- targeting peptides and 
antisense oligonucleotides to CP05, efficient delivery 
of these antisense RNAs to skeletal muscle in a mouse 
model of Duchenne muscular dystrophy was achieved197. 
As an alternative strategy to incorporation of targeting 
ligands directly in the extracellular vesicle membrane, 
it is also possible to incorporate artificial lipids into 
extracellular vesicle membranes, where they can aid 
in coupling of tissue- targeting antibodies or homing 
peptides with the extracellular vesicle surface and thus 
influence the biodistribution of therapeutic extracellular 
vesicles198.
Besides modification with proteins/peptides, there is 
growing interest in functionalizing extracellular vesicles 
with RNA aptamers to control their targeting. In this 
regard, a bacteriophage Φ29 RNA, which has a three- way 
junction allowing its self- association, has been engi-
neered to incorporate a membrane- targeting cholesterol 
moiety, a prostate- specific membrane antigen or RNA 
aptamer, and an epidermal growth factor receptor 
RNA aptamer199. This RNA trimer composite incorpo-
rated itself spontaneously into membranes of extra-
cellular vesicles ex vivo. These decorated extracellular 
vesicles could then be loaded with RNA cargo (such as 
anticancer siRNAs) to inhibit tumour growth in mouse 
models. Cancer cell- targeting aptamers were also suc-
cessfully conjugated to a hydrophobic diacyl lipid tail and 
incorporated in extracellular vesicle membranes follow-
ing their loading with anticancer drugs200. Extracellular 
vesicle functionalization has also been performed chemi-
cally (via reaction between aptamer-conjugated aldehyde 
and the amino group of membrane proteins incorpo-
rated into extracellular vesicles), whereby extracellular 
vesicles from bone marrow stromal cells were equipped 
with a bone marrow- specific RNA aptamer201. These 
functionalized extracellular vesicles were then efficiently 
targeted to the bone marrow after intravenous injection 
in mice and promoted bone regeneration. By con trast, 
non- functionalized extracellular vesicles primarily 
accumulated in the liver and lungs and did not have 
beneficial effects on bone regeneration201.
Overall, a wide variety of specific targeting strategies 
are being explored for extracellular vesicle delivery. One 
major caveat of these strategies, however, is that such 
ligands in the form of non- protected oligonucleotides 
and peptides/proteins exposed on the surface of the 
extracellular vesicle may be digested off in biofluids by 
RNases and proteases, respectively, thereby preventing 
targeting202,203.
More global approaches for directing tissue accu-
mulation of extracellular vesicles following intravenous 
administration include chemical modification of their 
surfaces. For example, treatment with neuraminidase 
to neutralize the negative charges on extracellular ves-
icles contributed by polysaccharides and glycosylated 
phospholipids reduced extracellular vesicle targeting 
to the liver, with a larger proportion of vesicles taken 
up by other organs, such as the brain, after intra venous 
injection in mice204. Engineered glycans can also be 
displayed on the surface of extracellular vesicles, as 
these moieties appear to be important for extracellular 
vesicle recognition and uptake by recipient cells205,206. 
Increased cellular uptake in general can be achieved 
by the addition of cationic lipids (for example, in the 
form of Lipofectamine) to the surface of extracellular 
vesicles207, by increasing macropinocytosis with an 
arginine- rich cell- penetrating peptide exposed on the sur-
face of the extracellular vesicles208 or by inducing receptor 
clustering on recipient cells209.
Increasing cytosolic delivery of the RNA cargo. Cytosolic 
delivery of extracellular vesicle content can potentially 
be improved by enhancing the fusogenic properties of 
extracellular vesicle membranes, which should result in 
the direct deposition of cargo RNA into the cytoplasm 
of the cell. Direct fusion of the extracellular vesicles with 
the plasma membrane can be achieved by incorporating 
fusion proteins, such as syncytin 1, syncytin 2 and epi-
thelial fusion failure 1 protein210, into their membranes. 
Furthermore, the gap junction protein connexin 43 is 
present in the extracellular vesicle membrane and can 
create a channel in the plasma membrane that allows pas-
sage of oligonucleotides into the cytosol211. On the basis 
of the similarity between extracellular vesicles and viral 
particles, incorporation of viral proteins, such as vesi-
cular stomatitis virus glycoprotein183, into extracellular 
vesicles is an appealing strategy to target extra cellular ves-
icles to specific cell types and organs while also improv-
ing functional delivery of RNA, albeit at the risk of 
introducing antigenic proteins113,212. For escape from 
the endosomal pathway, ideas can be sought from bac-
teria and viruses. Some enveloped and non- enveloped 
viruses (for example, adeno- associated virus and influ-
enza virus) are taken up by endocytosis and through 
pH- sensitive fusion proteins use the acidic pH of the 
endosomal compartment to promote membrane fusion 
between the endosomal and vesicular membranes213–215. 
Many species of pathogenic bacteria produce pore- 
forming toxins to escape from the degradative route 
following their uptake into host cell endosomes216–218. 
Such proteins could be engineered into extracellular 
vesicle membranes. Addition of compounds such as 
chloroquine that block acidification of the endoso-
mal compartment and release of viruses paradoxically 
enhanced extravesicular delivery in one of the studies, 
possibly through a protein sponge effect leading to swell-
ing and bursting of the endosomes219. Other compound 
found to increase endosomal escape was small molecule 
UNC10217832A219.
For liposome- based delivery, increased efficiency 
of endosomal escape was achieved by inclusion of an 
amine- rich polymer (polyethylene imine)220. While this 
may not be directly applicable to extracellular vesicles, it 
does highlight the existence of compounds that can spe-
cifically increase rates of endosomal escape and might 
improve intercellular delivery of extracellular vesicle 
content, with the possibility of combining liposome 
components with extracellular vesicles221.
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Potential clinical applications
Extracellular vesicles show promise for clinical appli-
cations both as biomarkers and as therapeutic delivery 
vehicles. Here we focus on uses of their RNA cargo, but 
proteins, lipids and glycans can all be informative as bio-
markers that carry the information about their cellular 
source, whereby their make- up informs on the physiolog-
ical state, with changes in composition often associated 
with a disease state. With their use as biomarkers, the 
main issue is detecting the subset of extracellular vesicles 
from a particular tissue in a sea of vesicles from other cell 
sources in biofluids. For therapy, extracellular vesicles can 
be used to deliver not only RNA but also proteins and 
drugs and combinations thereof. Issues remain concern-
ing best practices for isolating large numbers of clinical 
grade quality vesicles, loading them and directing their 
biodistribution to target tissues. In most scenarios they 
would be used to promote delivery of therapeutic cargo 
— be it functional RNA or protein — to the diseased 
tissue or tumour and would need to be readministered 
repeatedly throughout the disease state. Nevertheless, 
extracellular carriers can also serve as carriers of CRISPR 
technology to induce pathological error correction, and 
in this case they might be effective in a single dose.
Use of extracellular vesicle RNA cargo in diagnostics. 
RNAs in extracellular vesicles are in essence a snapshot 
of the content and state of the cells that secrete them 
and are therefore very useful for biomarker discovery61. 
Extracellular vesicles are found in a wide variety of bio-
fluids, including serum/plasma, urine, saliva, cerebro-
spinal fluid and breast milk222,223. An advantage of using 
extracellular vesicle- derived RNAs as biomarkers is that 
they are protected from degradation by RNases and thus 
are quite stable, and that the vesicles display on their 
surface the antigenic markers of the cells from which 
they were derived, allowing enrichment of vesicles from 
a particular tissue source (for example, using antibody 
capture for the enrichment of tumour- derived vesicles 
in serum224). Many new sensitive technologies, such as 
Droplet Digital reverse transcription–PCR are being 
used to enhance detection of specific RNA species in 
extracellular vesicles225.
RNAs can serve as biomarkers based on the muta-
tions, splice variants and fused mRNAs as well as alter-
ations in levels of specific RNAs associated with various 
disease states. The first example using extracellular ves-
icles in biofluids was the detection of a tumour- specific 
mRNA: mutant epidermal growth factor receptor in 
serum of patients with glioblastoma24. In other examples, 
elevated levels of specific miRNAs have been found in 
cerebrospinal fluid from patients with glioblastoma226, 
patients with Alzheimer disease and Parkinson disease227, 
and patients with breast cancer228. Changes in levels of 
mRNA splice variants are detected in urine from patients 
with myotonic dystrophy229. lncRNA profiles in blood 
samples from patients with type 2 diabetes correlate with 
heart functions230. This biomarker application of extracel-
lular vesicles has already been successfully translated into 
the clinical setting. Currently, mutated mRNAs in extra-
cellular vesicles and other carriers in plasma are being 
used as biomarkers for the diagnosis of haematol ogical 
disorders231 (for example, NeoLAB liquid biopsy from 
NeoGenomics Laboratories) and for prognostic assess-
ment of prostate, lung and other solid tumours232,233  
(for example, ExoDx prostate test from Bio- Techne).
Therapeutic RNA delivery via extracellular vesicles. 
There is tremendous interest in using extracellular vesi-
cles as vehicles to deliver RNA therapeutics. Extracellular 
vesicles as therapeutic carriers have several advantages: 
they can be obtained from a variety of sources, including 
the patient’s own extracellular vesicles (in which case they 
would be immune neutral); they protect the cargo within 
a lipid bilayer; they provide a membrane platform for dis-
playing ligands; and they can carry not only RNA but also 
other therapeutic agents at the same time. At the present 
time, these applications are still limited by the inherent 
heterogeneity of extracellular vesicles and the inability 
to achieve a fully characterized pure extra cellular vesicle 
population. Extracellular vesicle preparations being used 
for preclinical trials are more appropriately referred to as 
‘secretomes’ as they contain a mixture of extracellular ele-
ments234,235. Despite these limitations, therapeutic RNA 
delivery via extracellular vesicles has already entered 
clinical investigations (see reF.150 for a review). Preclinical 
studies have shown that unmodified mesenchymal stem 
cell- derived extra cellular vesicles are distributed broadly 
after intra venous injection236,237 and can ameliorate the 
effects of various diseases in the liver, brain, heart, kid-
neys, lungs, skeletal muscle and immune system238. There 
are now also strategies in place to obtain extracellular 
vesicles in considerable amounts from various sources, 
such as commonly used cells that can be expanded on a 
large scale (for example, mesenchymal stem cells172,239, 
red blood cells240 and HEK293 cells241), biofluids that are 
readily available in large volumes (for example, bovine 
milk242 and human plasma167) and even plant materials 
(for example, grapefruit243 and ginger167). Vesicles and 
therapeutic agents generated from plants and other food 
items have the advantage that they fall into the category 
of natural substances and as such are not under the strict 
guidelines of the US Food and Drug Administration for 
clinical trials244. Furthermore, as discussed earlier, extra-
cellular vesicles can be further modified to be loaded 
with cargo, generating ‘designer’ vesicles with increased 
production, cargo loading and/or targeting for improved 
therapeutic outcome.
Five basic variations on the theme of using extra-
cellular vesicles as therapeutic vehicles are being tested 
preclinically or in clinical trials: implantation of donor 
cells, such as mesenchymal stem cells, which release 
extracellular vesicles on site; injection of purified, 
unmodified extracellular vesicles from cultured donor 
cells; injection of purified extracellular vesicles that have 
been modified for targeting or loading of cargo in vitro; 
injection of extracellular vesicles enriched in cargo of 
interest and/or with enhanced targeting/uptake prop-
erties from genetically modified cells; and implanta-
tion of genetically modified cells that release modified 
extracellular vesicles in vivo (Fig. 4). A few examples of 
these strategies taken from a large literature are provided 
here. First, mesenchymal stem cell- derived extracellular 
vesicles with their intrinsic composition of RNAs and 
Nature reviews | Molecular cell Biology
R e v i e w s
proteins are being evaluated for treatment of cerebellar 
ataxia (ClinicalTrials.gov identifier NCT01649687), bone 
repair245 and regeneration of macular holes in the eye 
(NCT03437759), although the role of specific RNAs in 
therapeutic efficacy has not yet been defined. Extensive 
effort is directed at loading isolated extra cellular vesi-
cles and adding targeting moieties to their surface to 
improve cargo delivery. For example, mesenchymal 
stem cell- derived extracellular vesicles transfected with 
miR-124 — an miRNA most abundantly expressed in the 
central nervous system and negatively associated with 
neural progenitor differentiation — are being tested as 
treatment for ischaemic stroke (NCT03384433), and 
mesenchymal stem cell- derived extracellular vesicles 
loaded with an miRNA against mutant KRAS are being 
tested as a therapy for pancreatic cancer (NCT03608631). 
In another example, loading of extracellular vesicles with 
cholesterol- conjugated siRNA to huntingtin mRNA has 
been shown to be effective in lowering levels of the pro-
tein in a mouse model of Huntington disease171. As dis-
cussed earlier, including a bone- targeting aptamer on the 
surface of extracellular vesicles derived from bone mar-
row stromal cells is an efficient strategy to therapeutically 
target the bone marrow in a mouse model of osteoporo-
sis201. It is also possible to harvest extracellular vesicles 
from genetically modified producer cells presenting tar-
geting peptides, load them with desired cargo and admin-
ister them in vivo. This strategy alleviated pathology in a 
mouse model of Duchenne muscular dystrophy, where 
extracellular vesicles were designed to target muscle and 
loaded with splice- correcting antisense nucleotides tar-
geting dystrophin (the alteration of which causes pathol-
ogy of Duchenne muscular dystrophy)197. On the front of 
using entire cells rather that purified extracellular vesicle 
administration, preclinical studies have explored genet-
ically modified glioma cells expressing high levels of a 
cluster of miRNAs (which are incorporated into extra-
cellular vesicles) to suppress growth of non- modified gli-
oma cells in mouse brain246. In another study, increased 
yields of extracellular vesicles from HEK293T cells 
loaded with mRNA for the antioxidant enzyme cata-
lase with ligands for neuronal targeting and endoso-
mal escape were effective in combatting neurotoxicity 
and Parkinson disease- associated neurodegeneration 
in mice after subcutaneous implantation161.
Potential advantages associated with use of extra-
cellular vesicles compared with other RNA delivery 
strategies, such as synthetic lipid nanoparticles or naked 
modified RNA molecules, include lower immunogenicity 
and toxicity241,247, better ability to cross cell and tissue 
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• Bone marrow-derived MSCs
for bone healing245
• MSC-derived extracellular vesicles
for ischaemic stroke (NCT03384433)
• MCS-derived extracellular vesicles for
macular holes in the eye (NCT03437759)
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Fig. 4 | Different strategies for using extracellular vesicles for therapeutic applications. Examples of therapeutic 
applications of extracellular vesicles that have resulted in either preclinical assessment or clinical trials (references to 
primary research or clinical trials are given). Generally , there are five strategies that can be used: implantation of donor cells, 
such as mesenchymal stem cells (MSCs), which release extracellular vesicles on- site (1); injection of purified, unmodified 
extracellular vesicles from cultured donor cells (2); injection of purified extracellular vesicles that have been modified for 
targeting or loading of cargo in vitro (3); injection of extracellular vesicles enriched in the cargo of interest and/or with 
enhanced targeting/uptake properties from genetically modified cells (4); and implantation of genetically modified cells 
that release modified extracellular vesicles in vivo (5). AAV, adeno- associated virus; siRNA , small interfering RNA.
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barriers21,110 and the potential to achieve more efficient 
delivery into cells248, while maintaining the possibility of 
incorporating targeting molecules and of loading both 
endogenous and synthetic RNA cargo. There is also 
potential for the use of extracellular vesicles in combina-
torial therapeutic approaches. An emerging strategy of 
combining extracellular vesicle- mediated delivery with 
gene therapy showed improved therapy for hearing loss 
when adeno- associated viruses harbouring therapeutic 
transgenes were packaged into extracellular vesicles in 
a mouse model of hereditary deafness249. Extracellular 
vesicles250 and exosome–liposome hybrids251 can also be 
used for delivery of Cas9 and potentially the guide RNA 
as well for CRISPR gene editing.
Some of the first clinical trials using extracellular 
vesicles involved their use as vaccines, specifically those 
targeting tumours. In this case, dendritic- cell- derived 
extracellular vesicles harbouring on their surface 
major histocompatibility complexes, which before injection 
were pulsed with tumour- specific peptides, thereby pro-
viding a platform for efficient delivery of immunogenic 
tumour antigens, were injected into patients (see, for 
example, reF.252). In further development of extracellu-
lar vesicles as vaccines, it is possible that extracellular 
vesicle delivery of mRNAs for pathogenic proteins into 
dendritic cells (see, for example, reF.253) might potenti-
ate vaccination without the need to generate and inacti-
vate pathogenic viruses or bacteria. Similarly, dendritic 
cell- derived extracellular vesicles can be loaded with 
total tumour RNA or lysate, providing an abundant 
source of tumour- specific antigens254. In another avenue 
of using extracellular vesicles in antitumour vaccination, 
it was shown that tumour- derived extracellular vesicles 
can promote the antitumorigenic responses in dendritic 
cells. In this case extracellular vesicles from the tumour 
can be used directly or could be used for preloading den-
dritic cells before their implantation into the patient (as 
dendritic cell- based antitumour vaccines), with the latter 
showing so far greater therapeutic potential.
Given the promising results from early studies of 
extracellular vesicles as therapeutics, substantial invest-
ment is being made in this area, both from funding 
sources such as the US National Institutes of Health 
(with 302 currently funded grants) and from venture 
capital firms (at least ten biotechnology companies).
Conclusions and perspective
While there is consensus that RNAs in extracellular 
vesicles mediate communication among cells, and there 
are demonstrated examples of specific RNAs carried 
by extracellular vesicles from one cell type mediating 
defined phenotypic effects on target cells, many ques-
tions remain to be resolved before we will be able to fully 
decipher this complex language. There are a variety of 
types of extracellular vesicles that differ in size and pro-
tein, lipid and RNA cargo. So far, attempts to character-
ize unique extracellular vesicle subclasses have proved 
challenging, in large part owing to technical and bio-
logical limitations and challenges involved in separation 
and molecular analysis of these nanoscale structures. 
Moreover, the RNA content of extra cellular vesicles is 
quite complex, mostly comprising small non- coding 
RNAs, the function of most of which are just beginning 
to be elucidated. There is growing evidence that differ-
ent extracellular vesicle subclasses carry different RNA 
cargo, but a comprehensive cataloguing of this cargo 
awaits the development of efficient methods to iden-
tify and separate extracellular vesicle subclasses. It is 
possible that some extracellular vesicles have a higher 
content of functional RNAs and others serve more as 
‘rubbish bags’ for the source cell (still, jettisoning of 
certain RNAs can have functional consequences for 
both source cells and recipient cells). In terms of extra-
cellular vesicle- mediated signalling, the modes by which 
extracellular vesicle subclasses are ‘addressed’ to differ-
ent recipient cell types await delineation. Although we 
know miRNAs and mRNAs in extracellular vesicles 
can be transferred to and be active in recipient cells, it 
remains to be determined what percentage of the RNA 
cargo performs functions and what percentage is lost to 
degradation (or is simply not functional in the recipient 
cell). A key issue here is the endosomal escape routes 
of RNA in extracellular vesicles, as this step appears to 
be the major bottleneck in efficient functional delivery 
of cargo. Given the apparent roles of extracellular ves-
icles in physiology and disease, understanding these 
issues is critical to providing insights into pathogenic 
mechanisms and potential therapeutic interventions. In 
this Review, we have provided a platform of the current 
state of knowledge of RNA transported in extracellular 
vesicles on which the field can build another level of 
understanding. In parallel, there is a burgeoning field 
of nanoparticles that can efficiently carry mRNA and 
siRNA to cells and escape the endosome (see, for exam-
ple, reFs255,256). It will be important for the extracellular 
vesicle and nanoparticle/liposome fields to engage in 
dialogue and combine the best properties of both for 
therapeutic applications257.
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